Billy W. Loo
United States of America
Dr. Loo is a physician-scientist Radiation Oncologist and Bioengineer who leads the Thoracic Radiation Oncology program at Stanford Cancer Institute. His clinical specialties are state-of-the-art radiation therapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR) and 4-D image-guided radiation therapy for lung tumors and radiosurgery for brain metastases. His research is in clinical trials and implementation of new treatment techniques for lung cancer, development of new medical imaging methods for measuring organ function and predicting response to cancer treatment, and development of next generation radiation treatment technologies and studying their unique biological effects. Dr. Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member, chair, or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, including the National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR), and American Society of Radiation Oncology (ASTRO).
My main clinical specialties are radiation treatment of lung cancer and head & neck cancer, and I serve as the Thoracic Radiation Oncology Program Leader. My clinical research interests include 4-D multimodality imaging of tumor and organ motion using CT, PET, and MR; novel functional/metabolic imaging of tumor hypoxia and lymphatic drainage; and implementation and clinical trials of high-precision image-guided radiation therapy including 4-D IMRT, dynamic conformal arc radiotherapy (DCART) and volumetric modulated arc therapy (VMAT), and stereotactic ablative radiotherapy (SABR). My preclinical and translational research interests include novel functional imaging of inflammation as a mechanism of late normal tissue radiation injury, novel reconstruction and processing methods for 4-D imaging data to reduce artifacts and extract functional/physiologic information, and the radiobiology of tumor hypoxia and SABR.